Table 2.
MBC clinical and histological characteristics.
| Study Year |
Clinical presentation | Mean tumor size (cm | T stage (TNM) (n) |
Tumor histology (n) | Tumor grade (n | Lymphovascular invasion (n | Positive ER (n)- | Positive PR (n) | Positive Her2 (n | Ki67 > 20% (n |
|---|---|---|---|---|---|---|---|---|---|---|
|
Albo 2003 |
Mass (85.7 %) Nipple discharge (14.3 %) |
1.9 (0.5–3.8) | T1 to T2 | IDC (7) | Grade 2 (5) Grade 3 (2) |
– | 7 (100.0 %) | 1 (14.3 %) | 3 (42.9 %) | – |
|
Cimmino 2004 |
Mass (83.3 %) Nipple discharge (16.7 %) |
1.6 (0.7–2.8) | T1 to T2 | IDC (4) IPC (1) DCIS (1) |
Grade 1 (1) Grade 2 (3) Grade 3 (1) |
2 (33.3 %) | 4 (66.7 %) | – | – | – |
|
De Cicco 2004 |
– | – | Tis (2) T1 (10) T2 (3) |
IDC (11) IPC (5) DCIS (2) |
Grade 1 (1) Grade 2 (9) Grade 3 (2) |
– | 18 (100.0 %) | 12 (66.7 %) | – | 7 (38.9 %) |
|
Gentilini 2007 |
– | – | T1 (23) T2 (3) |
IDC (23) IPC (3) DCIS (3) Other (3) |
Grade 1 (11) Grade 2/3 (21) |
– | 31 (96.9 %) | 25 (78.1 %) | 5 (15.6 %) | 17 (53.1 %) |
|
Golshan 2007 |
Mass (83.3 %) | 1.7 (0.8–3.0) | – | IDC (6) | Grade 2 (4) Grade 3 (2) |
– | 6 (100.0 %) | 5 (83.3 %) | 2 (33.3 %) | – |
|
Goyal 2004 |
– | – | T1 (4) T2 (5) |
IDC (9) | Grade 1 (1) Grade 2 (8) |
– | – | – | – | – |
|
Koukouras 2012 |
– | – | – | IDC (10) Mucoepidermoid (1) |
– | – | – | – | – | – |
|
Martin 2017 |
– | 2.2 (5–40) | T1 to T2 | IDC (12) IPC (2) DCIS (1) |
Grade 1 (2) Grade 2 (12) Grade 3 (1) |
– | 15 (100.0 %) | 15 (100.0 %) | 2 (13.3 %) | 2 (13.3 %) |
|
Port 2001 |
Mass (83.3 %) Nipple discharge (6.3 %) |
1.3 (0.1–1.3) | T1 to T2 | IDC (14) IPC (1) DCIS (1) |
Grade 1 (0) Grade 2 (6) Grade 3 (5) |
5 (31.3 %) | 15 (93.8 %) | – | – | – |
|
Rusby 2006 |
Mass (83.0 %) | 1.8 (0.1–4) | T1 (19) T2 (12) |
IDC (28) ILC (1) IDC/ILC (1) Mucinous (1) |
Grade 1 (2) Grade 2 (18) Grade 3 (11) |
– | 29 (93.5 %) | 28 (90.3 %) | 5 (16.1 %) | 17 (54.8 %) |
|
Simsek 2018 |
– | – | – | – | – | – | – | – | – | – |
|
Suehiro 2015 |
Mass (100.0 %) | 1.7 (1.0–2.5) | – | IDC (3) | Grade 1 (2) Grade 3 (2) |
– | 3 (100.0 %) | 3 (100.0 %) | 0 (0.0 %) | 1 (33.3 %) |
IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; IP: Intracystic Papillary Carcinoma; DCIS: Ductal Carcinoma in Situ; ER: Estrogen Receptor; PR: Progesterone Receptor; -: data not available.